Stock Scorer

Altimmune, Inc. (ALT)

Altimmune, Inc. reported revenue of 26K USD for the quarter ending 31 December 2025, up 420.0% from 5K a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q4 '25 · ending 31 December 2025 26K +420.0%
Operating Income Q2 '26 · ending 30 June 2026 -26.2M —
Net Income Q2 '26 · ending 30 June 2026 -22.8M —
Operating Cash Flow Q2 '26 · ending 30 June 2026 -24.2M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -24.3M —
Shares Outstanding Q2 '26 · ending 30 June 2026 185.4M +145.5%
EPS Q2 '26 · ending 30 June 2026 -0.77 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 41K-94.5M-88.1M-67.5M
20242024-12-31 20K-103.2M-95.1M—
20232023-12-31 426K-95.9M-88.4M-75.9M
20222022-12-31 -68K-87.7M-84.7M-62.7M
20212021-12-31 4.4M-96.9M-97.1M-90.4M
20202020-12-31 8.2M-54.8M-49M-34.5M
20192019-12-31 5.8M-21.5M-20.5M-9.6M
20182018-12-31 10.3M-42.8M-39.2M-10.4M
20172017-12-31 10.7M-52M-46.4M-20.3M
20162016-12-31 3.2M-11.1M-11.1M-6.5M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q4 '252025-12-3126K
Q3 '252025-09-305K
Q2 '252025-06-305K
Q1 '252025-03-315K
Q4 '242024-12-315K
Q3 '242024-09-305K
Q2 '242024-06-305K
Q1 '242024-03-315K
Q4 '232023-12-3137K
Q3 '232023-09-30362K
Q2 '232023-06-306K
Q1 '232023-03-3121K
Q4 '222022-12-31-110K
Q3 '222022-09-302K
Q2 '222022-06-308K
Q1 '222022-03-3132K
Q4 '212021-12-313.3M
Q3 '212021-09-30158K
Q2 '212021-06-30137K
Q1 '212021-03-31838K

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-26.2M
Q1 '262026-03-31-24.2M
Q4 '252025-12-31-28.9M
Q3 '252025-09-30-20.9M
Q2 '252025-06-30-22.9M
Q1 '252025-03-31-21.8M
Q4 '242024-12-31-24.9M
Q3 '242024-09-30-24.8M
Q2 '242024-06-30-26.7M
Q1 '242024-03-31-26.8M
Q4 '232023-12-31-33.6M
Q3 '232023-09-30-22.5M
Q2 '232023-06-30-18M
Q1 '232023-03-31-21.8M
Q4 '222022-12-31-23.1M
Q3 '222022-09-30-24.8M
Q2 '222022-06-30-20.4M
Q1 '222022-03-31-19.5M
Q4 '212021-12-31-24M
Q3 '212021-09-30-33.2M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-22.8M
Q1 '262026-03-31-22.6M
Q4 '252025-12-31-27.4M
Q3 '252025-09-30-19M
Q2 '252025-06-30-22.1M
Q1 '252025-03-31-19.6M
Q4 '242024-12-31-23.2M
Q3 '242024-09-30-22.8M
Q2 '242024-06-30-24.6M
Q1 '242024-03-31-24.4M
Q4 '232023-12-31-31.6M
Q3 '232023-09-30-20.7M
Q2 '232023-06-30-16.1M
Q1 '232023-03-31-20.1M
Q4 '222022-12-31-21.7M
Q3 '222022-09-30-23.5M
Q2 '222022-06-30-20.1M
Q1 '222022-03-31-19.4M
Q4 '212021-12-31-23.9M
Q3 '212021-09-30-33.5M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-24.2M
Q1 '262026-03-31-20.9M
Q4 '252025-12-31-19.4M
Q3 '252025-09-30-11.9M
Q2 '252025-06-30-19.4M
Q1 '252025-03-31-16.8M
Q4 '242024-12-31-18.3M
Q3 '242024-09-30-27.1M
Q2 '242024-06-30-18.1M
Q1 '242024-03-31-16.4M
Q4 '232023-12-31-16.5M
Q3 '232023-09-30-20.5M
Q2 '232023-06-30-19.4M
Q1 '232023-03-31-19.4M
Q4 '222022-12-31-17.3M
Q3 '222022-09-30-15.1M
Q2 '222022-06-30-16.7M
Q1 '222022-03-31-13.5M
Q4 '212021-12-31-22M
Q3 '212021-09-30-17.8M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-24.3M
Q1 '262026-03-31-21M
Q4 '252025-12-31-19.4M
Q3 '252025-09-30-11.9M
Q4 '232023-12-31-16.5M
Q3 '232023-09-30-20.5M
Q2 '232023-06-30-19.4M
Q1 '232023-03-31-19.5M
Q4 '222022-12-31-17.3M
Q3 '222022-09-30-15.1M
Q2 '222022-06-30-16.7M
Q1 '222022-03-31-13.5M
Q4 '212021-12-31-22.1M
Q3 '212021-09-30-17.8M
Q2 '212021-06-30-26.6M
Q1 '212021-03-31-23.8M
Q4 '202020-12-31-13.4M
Q3 '202020-09-30-9.6M
Q2 '202020-06-30-7.2M
Q1 '202020-03-31-4.4M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30185.4M
Q1 '262026-03-31124.5M
Q3 '252025-09-3089.4M
Q2 '252025-06-3081.5M
Q1 '252025-03-3175.5M
Q3 '242024-09-3071.1M
Q2 '242024-06-3070.9M
Q1 '242024-03-3170.8M
Q3 '232023-09-3053.6M
Q2 '232023-06-3050.7M
Q1 '232023-03-3150.1M
Q3 '222022-09-3049.3M
Q2 '222022-06-3047.5M
Q1 '222022-03-3144M
Q3 '212021-09-3041.4M
Q2 '212021-06-3041.4M
Q1 '212021-03-3138.9M
Q3 '162016-09-3065.8M
Q2 '162016-06-3065.2M
Q1 '162016-03-3164.4M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-0.77
Q1 '262026-03-31-0.92
Q4 '252025-12-31-1.00
Q3 '252025-09-30-1.07
Q2 '252025-06-30-1.18
Q1 '252025-03-31-1.26
Q4 '242024-12-31-1.34
Q3 '242024-09-30-1.57
Q2 '242024-06-30-1.64
Q1 '242024-03-31-1.61
Q4 '232023-12-31-1.67
Q3 '232023-09-30-1.55
Q2 '232023-06-30-1.64
Q1 '232023-03-31-1.74
Q4 '222022-12-31-1.78
Q3 '222022-09-30-1.90
Q2 '222022-06-30-2.23
Q1 '222022-03-31-2.41
Q4 '212021-12-31-2.35
Q3 '212021-09-30-1.96